ABOUT GIGARESEARCH
GIGARESEARCH is a research-peptide knowledge base in compound index format. Each entry covers one compound: mechanism of action, evidence grades A-F, FAQs, peer-reviewed citations, and links to the underlying primary literature.
OUR MISSION
Make peer-reviewed peptide research accessible without diluting the science. Every compound page cites primary literature with PubMed PMIDs and ClinicalTrials.gov NCTs. Evidence grades reflect study quality, not commercial interest.
METHODOLOGY
We aggregate peer-reviewed peptide data. Every compound entry starts with a structured research brief built from PubMed PMIDs, ClinicalTrials.gov NCTs, and journal DOIs. Each claim is paired with a citation before draft. Each draft is then graded against the rubric at /about/research-process. We do not generate evidence. We summarize and grade what the literature already says.
PUBLISHER
GIGARESEARCH is published by GigaCompounds LLC, organized under the laws of the U.S. state of Wyoming. The site is editorially independent from the storefront. Research peptides referenced on the site are available for purchase at gigacompounds.com, but evidence grades and FAQs are not adjusted to favor inventory.
FUNDING TRANSPARENCY
GIGARESEARCH is self-funded by GigaCompounds LLC. The company derives revenue from research-grade peptide sales at gigacompounds.com. There is no external investor, no pharmaceutical-company funding, no affiliate-network revenue. The site does not run display ads.
CONFLICT OF INTEREST DISCLOSURE
GigaCompounds LLC is affiliated with the research-peptide storefront at gigacompounds.com. Because of that affiliation, we link out to gigacompounds.com from compound pages and from billboard placements on the index. We present the research neutrally regardless. A compound that we do not stock receives the same coverage as a compound that we do. Evidence grades are anchored to study quality, not to inventory. We do not accept paid placement, sponsored entries, or advertorial. Where a compound is FDA-approved under a branded name (e.g. the GLP-1 / GIP dual agonist as separate FDA-approved class members), we link to the originator and note the regulatory status. No diagnostic or treatment claims are made.
EDITORIAL BOARD
Sign-off is currently handled by the GigaCompounds Research Desk, a composite editorial team. We are actively recruiting an individually-named PharmD or MD reviewer to take over compound-level sign-off · pending Q3 2026. The current desk profile lives at /reviewers/editorial-board.
EDITORIAL STANDARDS
See /editorial-policy for citation requirements, fact-check workflow, and correction policy. See /about/research-process for the evidence-grading rubric.
CONTACT
Editorial inquiries · editorial@gigacompounds.com. Corrections · corrections@gigacompounds.com.